This type of heading in media stories and press releases tends to drive your Sitemaster to distraction because there is almost invariably a major “may” or a “possibly” in the actual story when you get into the details. However, in this particular case there may be some justification for the headline. … READ MORE …
Filed under: Drugs in development | Tagged: cancer, CC-115, DNA-PKcs, inhibitor, repair | 2 Comments »
According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, Lynparza, olaparib, PARP | 4 Comments »
A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, inhibitor, PDE5, phosphdiesterase 5, recurrence, risk, surgery | 4 Comments »
According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: androgen, castration-resistant, CRPC, inhibitor, ODM-201, receptor | 10 Comments »
A Phase II clinical trial being coordinated by researchers at the University of Michigan Cancer Center is (as far as we know) the first trial ever to explore the potential of treatment for men with metastatic, castration-resistant prostate cancer (mCRPC) who carry the TMPRSS2-EPG fusion gene (as opposed to those who do not). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ABT-888, fusion, gene, inhibitor, PARP, TMPSS2-ERG, veliparib | 2 Comments »
There has been considerable interest in the ability of so-called “heat shock protein” (HSP) inhibitors to be used alone or in combination with other agents to delay the progression of a number of types of cancer, and of advanced forms of prostate cancer in particular. … READ MORE …
Filed under: Drugs in development | Tagged: heat shock protein, HSP, inhibitor, IPI-504, OGX-427, outcome, trial | 2 Comments »
A recent review article concludes with the statement, “5α-reductase inhibition does seem to have beneficial effects on prostate cancer incidence, and the role of [5α-reductase inhibitors (5-ARIs)] in combination with other agents should be further evaluated for the treatment of [castration-resistant prostate cancer (CRPC)].” … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: 5-ARI, 5α-reductase, abiraterone, inhibitor | 5 Comments »
According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: avanafil, ED, erctile dysfunction, inhibitor, PDE5 | Leave a comment »
In this news report we summarize studies dealing with:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: elderly, inhibitor, MAOA, progression, PSA, radical prostatectomy, recurrence | Leave a comment »
New animal research has suggested that the telomerase inhibitor imetelstat may have activity in the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: imetelstat, inhibitor, telomerase | 1 Comment »
GTx has announced a second Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone (LH) inhibitor (not an LHRH agonist or an LHRH antagonist), for first-line treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: GTx, GTx-758, inhibitor, LH, luteinizing hormone | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 